Clinical Trials

38 enrolled

Phase 2 Not yet recruiting

Cholangiocarcinoma

NCT07434843 2026-02-27

PEMIGIST

24 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT06906562 2026-02-17

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

40 enrolled

Pancreatic Neoplasms

NCT06302621 2026-01-15

Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

Phase 1 Recruiting

70 enrolled

Neoplasm Metastasis, Cholangiocarcinoma

NCT05267106 2025-12-30

FIGHT-209

Other hematologic neoplasm

83 enrolled 18 charts

CNS

Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms

NCT04659616 2025-12-19

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

Phase 1 Recruiting

32 enrolled

Leukemia, Myeloid, Acute

NCT04463771 2025-12-10

POD1UM-204

Phase 2 Active not recruiting

206 enrolled

Gynecologic

Neoplasm Metastasis, Endometrial Neoplasms

NCT06300528 2025-12-03

Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

27 enrolled

Lymphoid

Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03498521 2025-11-19

CUPISCO

529 enrolled 16 charts

Tumor-Agnostic

Neoplasms, Unknown Primary

NCT03011372 2025-11-18

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

47 enrolled 21 charts 1 FDA

Myeloid

Eosinophilia, Myeloproliferative Disorders

NCT03822117 2025-11-04

Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

111 enrolled 17 charts

Acrocephalosyndactylia

NCT04003610 2025-11-04

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

7 enrolled 10 charts

Acrocephalosyndactylia, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT03914794 2025-10-03

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

30 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03656536 2025-08-24

FIGHT-302

Phase 3 Terminated

167 enrolled

Cholangiocarcinoma

NCT02872714 2025-08-14

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

263 enrolled 20 charts

Acrocephalosyndactylia, Carcinoma, Transitional Cell

NCT02924376 2025-08-14

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

147 enrolled 22 charts 2 FDA

Acrocephalosyndactylia, Cholangiocarcinoma

NCT05253807 2025-08-05

FIGHT-210

8 enrolled 13 charts

Thoracic

Acrocephalosyndactylia, Carcinoma, Non-Small-Cell Lung, Recurrence

NCT06653777 2025-06-05

AcSé PEMI

40 enrolled

Other solid neoplasm

Solid Tumor, Miscellaneous

NCT04294277 2025-04-18

PEGASUS

2 enrolled 6 charts

Carcinoma, Transitional Cell

NCT05565794 2025-04-13

Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements

2 enrolled